Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
Neoadjuvant pertuzumab plus trastuzumab met of zonder chemotherapie: 5-jaarsoverlevingsdata
jun 2022 | Borstkanker